Next Article in Journal
BRCA1/2 Population Screening: Embracing the Benefits
Previous Article in Journal
Recent Trends in Breast, Cervical, and Colorectal Cancer Screening Test Utilization in Canada, Using Self-Reported Data from 2008 and 2012
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 4
10.3747/co.22.2719
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Dasatinib for a Child with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia and Persistently Elevated Minimal Residual Disease during Imatinib Therapy

by
K.H. Wu
1,2,
H.P. Wu
3,
T. Weng
2,
C.T. Peng
1,2,4 and
Y.H. Chao
5,6,*
1
School of Chinese Medicine, China Medical University, Taichung, Taiwan
2
Department of Pediatrics, Children’s Hospital, China Medical University, Taichung, Taiwan
3
Department of Pediatrics, Buddhist Tzu-Chi General Hospital, Taichung Branch, Taichung, Taiwan
4
Department of Biotechnology and Bioinformatics, Asia University, Taichung, Taiwan
5
Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan
6
School of Medicine, Chung Shan Medical University, Taichung, Taiwan
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(4), 303-306; https://doi.org/10.3747/co.22.2719
Submission received: 6 May 2015 / Revised: 7 June 2015 / Accepted: 5 July 2015 / Published: 1 August 2015

Abstract

Imatinib has improved outcomes in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (all). Minimal residual disease (mrd) is a useful tool for predicting leukemia relapse. However, there is no consensus on how to treat children with elevation of BCR-ABL transcripts but no evidence of hematologic relapse during chemotherapy combined with imatinib. Here, we report the case of a child with Ph+ all who had persistent elevation of mrd, but no evidence of hematologic relapse while receiving imatinib plus intensive chemotherapy. Dasatinib was substituted for imatinib because no suitable donor for allogeneic hematopoietic stem-cell transplantation (hsct) was available. Less-intensive chemotherapy with methotrexate and 6-mercaptopurine was administered concomitantly. No serious adverse events were encountered. With continuous dasatinib combined with chemotherapy, but no allogeneic hsct, our patient reached complete molecular remission and has been in complete molecular remission for more than 13 months. This report is the first about the long-term use of dasatinib in patients with Ph+ all and mrd elevation but hematologic remission during imatinib chemotherapy. In a similar situation, chemotherapy combined with dasatinib instead of allogeneic hsct could be considered to avoid hsct-related mortality and morbidity. Clinical trials are needed.
Keywords: dasatinib; Philadelphia chromosome; acute lymphoblastic leukemia; complete molecular remission; children dasatinib; Philadelphia chromosome; acute lymphoblastic leukemia; complete molecular remission; children

Share and Cite

MDPI and ACS Style

Wu, K.H.; Wu, H.P.; Weng, T.; Peng, C.T.; Chao, Y.H. Dasatinib for a Child with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia and Persistently Elevated Minimal Residual Disease during Imatinib Therapy. Curr. Oncol. 2015, 22, 303-306. https://doi.org/10.3747/co.22.2719

AMA Style

Wu KH, Wu HP, Weng T, Peng CT, Chao YH. Dasatinib for a Child with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia and Persistently Elevated Minimal Residual Disease during Imatinib Therapy. Current Oncology. 2015; 22(4):303-306. https://doi.org/10.3747/co.22.2719

Chicago/Turabian Style

Wu, K.H., H.P. Wu, T. Weng, C.T. Peng, and Y.H. Chao. 2015. "Dasatinib for a Child with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia and Persistently Elevated Minimal Residual Disease during Imatinib Therapy" Current Oncology 22, no. 4: 303-306. https://doi.org/10.3747/co.22.2719

APA Style

Wu, K. H., Wu, H. P., Weng, T., Peng, C. T., & Chao, Y. H. (2015). Dasatinib for a Child with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia and Persistently Elevated Minimal Residual Disease during Imatinib Therapy. Current Oncology, 22(4), 303-306. https://doi.org/10.3747/co.22.2719

Article Metrics

Back to TopTop